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1. Introduction 
Enzyme is a protein molecule acting as catalyst in enzyme reaction. Enzyme inhibition is a 
science of enzyme-substrate reaction influenced by the presence of any organic chemical or 
inorganic metal or biosynthetic compound due to their covalent or non-covalent interactions 
with enzyme active site. It is well known that all these inhibitors follow same rule to 
interplay in enzyme reaction. Present chapter introduces beginners with basic tenets of 
classic presumptions of enzyme inhibition, types of enzyme inhibitors, different models of 
enzyme inhibition with established examples cited in literature, and scientific basis of 
emerging immobilized enzyme technology in different applications. In the end, limitations 
of using classic presumptions and variants of enzyme inhibition are highlighted with new 
challenges to achieve best results. Present time, best approach is 'customize new technology 
with detailed analysis to make it highly efficient' in both drug discovery and enzyme 
biosensor industry. However, other applications are described in following chapters on 
pesticides, herbicides.  
2. What are enzyme inhibitors? 
The enzyme inhibitors are low molecular weight chemical compounds. They can reduce or 
completely inhibit the enzyme catalytic activity either reversibly or permanently 
(irreversibly). Inhibitor can modify one amino acid, or several side chain(s) required in 
enzyme catalytic activity. To protect enzyme catalytic site from any change, ligand binds 
with critical side chain in enzyme. Safely, chemical modification can be done to test inhibitor 
for any drug value.  
In drug discovery, several drug analogues are chosen and/or designed to inhibit specific 
enzymes. However, detoxification or reduced toxic effect of many antitoxins is also 
accomplished mainly due to their enzyme inhibitory action. Therefore, studying the 
aforementioned enzyme kinetics and structure-function relationship is vital to understand 
the kinetics of enzyme inhibition that in turn is fundamental to the modern design of 
pharmaceuticals in industries [Sami et al. 2011]. Enzyme inhibition kinetics behavior and 
inhibitor structure-function relationship with enzyme active site clarify the mechanisms of 
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enzyme inhibition action and physiological regulation of metabolic enzymes as evidenced in 
following chapters in this book. Some notable classic examples are: drug and toxin action 
and/or drug design for therapeutic uses e.g., iodoacetamide deactivates cys amino acid in 
enzyme side chain; methotrexate in cancer chemotherapy through semi-selectively inhibit 
DNA synthesis of malignant cells; aspirin inhibits the synthesis of the proinflammatory 
prostaglandins; sulfa drugs inhibit the folic acid synthesis essential for growth of pathogenic 
bacteria and so many other drugs. Many life-threatening poisons, e.g., cyanide, carbon 
monoxide and polychlorinated biphenols are all enzyme inhibitors.  
Conceptually, enzyme inhibitors are classified into two types: non-specific inhibitors and 
specific inhibitors.  
The enzyme inhibition reactions follow a set of rules as mentioned in following rules. 
Presently, computer based enzyme kinetics data analysis softwares are developed using 
following basic presumptions. 
1. Enzyme interacts with substrate in 1:1 ratio at active site to catalyze the reaction.  
2. Enzyme binds with substrate at active site in the form of a lock-key 3D arrangement for 
induced fit. 
3. Inhibitor active groups compete with substrate active groups and/or active groups at 
enzyme allosteric catalytic site in a synergistic manner or first cum first preference 
(competition) to make enzyme-inhibitor-substrate/enzyme-substrate/enzyme-inhibitor 
complexes.  
4. Enzyme-inhibitor-substrate complex formation depends on active free energy loss and 
thermodynamic principles. 
5. Enzyme and substrate or inhibitors react with each other as active masses and reaction 
progresses in kinetic manner of forward or backward reaction. 
6. Kinetic nature of inhibitor or substrate binding with enzyme is expressed as kinetic 
constants of a catalytic reaction. 
7. Enzyme reaction(s) are highly depend on physiological conditions such as pH, 
temperature, concentration of reactants, reaction period to determine the rate of reaction.  
8. Substrate and inhibitor molecules arrange over enzyme active site on specific sub 
unit(s) in 3D manner. As a result enzyme-substrate-inhibitor exhibit binding rates 
depend on allosteric sites or subunit-subunit homotropic or heterotropic interactions. 
9. Intermolecular forces between enzyme subunits, substrate or inhibitor active group 
interactions, physical properties of binding nature: electrophilic, hydrophilic, nucleophilic 
and metalloprotein nature; hydrogen bonding affect the overall enzyme reaction rates and 
mode of inhibition (3D orientation of inhibitor molecule on enzyme active site).  
Other factors are also significant in determining enzyme inhibition reaction as described in 
each individual inhibitor in following sections. For basic principles of enzyme units 
(apoenzyme, holoenzyme, co-factor, co-enzyme) in enzyme catalysis, active energy loss, 
Michaelis-Menton Equations, LeChatelier’s principle, Lineweaber-Burk and semi-log plots, 
apparent and actual plots, readers are requested to read text books [Schnell et al. 2003, 
Nelson, et al. 2008, Jakobowski 2010a, Strayer et al. 2011]. Our focus is enzyme inhibition 
mechanisms with examples in following description. For multisubstrate enzymes, ping-
pong mechanism, allosteric mechanisms, and diffusion kinetics, readers are requested to 
read original papers [Pryciak 2008, Bashor 2008, Jakobowski 2010b] 
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These inhibitors may act in reversible or irreversible manner. Non-specific irreversible non-
competitive inhibitors include all protein denaturating factors (physical and chemical 
denaturation factors). The specific inhibitors attack a specific component of the holoenzyme 
system. The action depends on increased amount of substrate or by other means of 
physiological conditions, toxins. Specific inhibitors can be described in several forms 
including; 1) coenzyme inhibitors: e.g., cyanide, hydrazine and hydroxylamine that inhibit 
pyridoxal phosphate, and, dicumarol that is a competitive antagonist for vitamin K; 2) 
inhibitors of specific ion cofactor: e.g., fluoride that chelates Mg2+ of enolase enzyme; 3) 
prosthetic group inhibitors: e.g., cyanide that inhibits the heme prosthetic group of cytochrome 
oxidase; and, 4) apoenzyme inhibitors that attack the apoenzyme component of the 
holoenzyme; 5) physiological modulators of reaction pH and temperature that denature the 
enzyme catalytic site.  
The apoenzyme inhibitors are of two types; i) Reversible inhibitors; their inhibitory action is 
reversible because they make reversible association with the enzyme, and, ii) Irreversible 
inhibitors; because they make inactivating irreversible covalent modification of an essential 
residue of the enzyme. Apoenzyme inhibitors show effect on Km and Vmax. The reversible 
apoenzyme inhibitors are also called metabolic antagonists. They are of three subtypes; a) 
competitive, b) uncompetitive and c) non-competitive or mixed type. For example: enzyme 
inhibitors are used in drug design. 
Discovery of useful new enzyme inhibitors used to be done by trial and error through 
screening a huge library of compounds against a target enzyme at allosteric catalytic site. 
This approach is still in use for compounds with combinatorial chemistry and high-
throughput screening technology as described in following description based on recent 
concepts [El-Metwally et al. 2010]. However, rational drug design as an alternative approach 
uses the three-dimensional structure of an enzyme's active site or transition-state 
conformation to predict which molecules might be ideal inhibitors as given an example of 
urease in chapter 11 in this book. 3D-structure shortens the long screening list towards a 
right set of novel inhibitor which kinetically characterizes and allows specific structural 
changes in amino acids of catalytic site chain to optimize inhibitor-enzyme binding. 
Alternatively, molecular docking and molecular mechanics are computer-based methods 
that predict the affinity of an inhibitor for an enzyme. In following description, a glimpse of 
these mechanisms is given on different types of inhibitors based on recent classic book [El-
Metwally et al. 2010]. Readers are requested to read other classic details from advanced text 
books [Dixon and Webb, 1979]. 
3. Irreversible inhibition  
The irreversible apoenzyme inhibitors have no structural relationship to the substrate and 
bind covalently. They also bind stable non-covalently with the active site of the enzyme or 
destroy an essential functional group of active site. So, irreversible inhibitors are used to 
identify functional groups of the enzyme active sites at which location they bind. Although 
inhibitors have limited therapeutic applications because they are usually act as poisons. A 
subset of irreversible inhibitors called suicide irreversible inhibitors, are relatively inactive 
compounds. They get activated upon binding with the active site of a specific enzyme. After 
such binding, the suicide irreversible inhibitor is activated by the first few intermediary 
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steps of the biochemical reaction - like the normal substrate. However, it does not release 
any product because of its irreversible binding at the enzyme active site. Inhibitors make use 
of the normal enzyme reaction mechanism to get activated and subsequently inactivate the 
enzyme. Due to this very nature, suicide irreversible inhibitors are also called mechanism-
based inactivators or transition state analog inhibitors. Thus, inhibitor exploits the transition 
state stabilizing effect of the enzyme, resulting in a better binding affinity (lower Ki) than 
substrate-based designs. An example of such a transition state inhibitor is active form of the 
antiviral drug oseltamivir (Tamiflu; see Figure 1); this drug mimics the planar nature of the 
ring oxonium ion in the reaction of the viral enzyme neuraminidase [El-Metwally et al. 
2010]. After drug activation in the liver, the drug replaces sialic acid as the normal substrate 
found on the surface proteins of normal host cells. It prevents the release of new viral 
particles from infected cells. It has been used to treat and prevent Influenza virus A and 
Influenza virus B infections. Most of such inhibitors are classified as tight-binding 
competitive inhibitors in other references of enzymes. However, their reaction kinetics is 
essentially irreversible. 
O
O
H2N
HN
O
 
Fig. 1. The transition state analog oseltamivir - the viral neuraminidase inhibitor. 
The present art of drug discovery and design of new drugs is based on suicidal irreversible 
inhibitors. Chemicals are synthesized based on knowledge of 3D conformation of substrate-
active site binding at specific binding rates in presence of co-factors, co-enzyme (enzyme 
reaction mechanisms) to inhibit at specific enzyme active site with minimal side-effects due 
to its non-specific binding nature. Transition state analogs are extremely potent and specific 
inhibitors of enzymes because they have higher affinity and stronger binding to the active 
site of the target enzyme than the natural substrates or products. However, exact design of 
drugs that precisely mimic the transition state is a challenge because of unstable structure of 
transition state in the free-state. Prodrugs undergo initial reaction(s) to form an overall 
electrostatic and three-dimensional intermediate transition state complex form with close 
similarity to that of the substrate. These prodrugs serve as guideline for drug development 
to form transition state suitable for stable modification; or, using the transition state analog 
to design a complementary catalytic antibody; called Abzyme. Example: Abzymes are used 
in catalytic antibodies and ribozymes in catalytic ribosomes [El-Metwally et al. 2010].  
 Abzymes are antibodies generated against analogs of the transition state complex of a 
specific chemical. The arrangement of amino acid side chains at the abzyme variable 
regions is similar to the active site of the enzyme in the transition state and work as 
artificial enzymes. For example, an abzyme was developed against analogs of the 
transition state complex of cocaine esterase, the enzyme that degrades cocaine in the 
body [El-Metwally et al. 2010]. Thus, this abzyme has similar esterase activity that is 
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used as injection drug to rapidly destroy cocaine in the blood of addicted individuals to 
decreasing their dependence on it.  
 Thrombin inhibition is common in saliva of leeches and other blood-sucking organisms. 
They contain the anticoagulant hirudin that irreversibly inhibits thrombin, and, to 
regain thrombin action synthesis of new thrombin molecules is required. This made it 
unsafe as an anticoagulation drug. However, based on hirudin structure, rational drug 
design synthesized 20-amino acids peptide known as bivalirudin that is safe for long-
term use because of its reversible effects on thrombin; despite its high binding affinity 
and specificity for thrombin.  
 Ornithine decarboxylase by difluoromethylornithine is used to treat African 
trypanosomiasis (sleeping sickness). The enzyme initially decarboxylates 
difluoromethylornithine instead of ornithine and releases a fluorine atom, leaving the 
rest of the molecule as a highly electrophilic conjugated imine. The later reacts with 
either a cysteine or lysine residue in the active site to irreversibly inactivate the enzyme.  
 Inhibition of thymidylate synthase by fluoro-dUMP. Imidazole antimycotic drugs are 
examples of such group that inhibit several subtypes of cytochrome P450 [Sharma, 
1990]. The mechanisms of toxicities and antidotes of irreversible inhibitors are of 
medical pathological importance. Because of the irreversible inactivation of the enzyme, 
irreversible inhibition is of long duration in the biological system because reversal of 
their action requires synthesis of new enzyme molecules at the enzyme gene-
transcription-translation level.  
 Inhibition of acetylcholine esterase (ACE) by diisopropylfluorophosphate (DPFP), the 
ancestor of current organophosphorus nerve gases (e.g., Sarin and Tabun) and other 
organophosphorus toxins (e.g., the insecticides Malathion and Parathion and 
chlorpyrifos). ACE hydrolyzes the acetylcholine into acetate and choline to terminate 
the transmission of the neural signal form the neuromuscular excitatory acetylcholine 
presynaptic cell to somatic neuromuscular junction (see Figure 2). DPFP as a potent 
neurotoxin inhibits ACE and acetylcholine hydrolysis. Failure of hydrolysis leads to 
persistent acetylcholine excitatory state and improper vital function particularly 
respiratory muscles that may lead to suffocation; with a lethal dose of less than 100 mg. 
DPFP inhibits other enzymes with the reactive serine residue at the active site, e.g., 
serine proteases such as trypsin and chymotrypsin, but the inhibition is not as lethal as 
that of acetylcholine esterase. Similar to DPFP, malaoxon the toxic reactive derivative 
from Malathion (after its metabolism by the liver) binds initially reversibly and then 
irreversibly (after dealkylation of the inhibitor) to the active site serine and inactivates 
ACE and other enzymes. Lethal doses of oral Malathion are estimated at 1 g/kg of body 
weight for humans.  
 Inhibition of ACE by these poisons leads to accumulation of acetylcholine that over-
stimulates the autonomic nervous system (including heart, blood vessels, and glands), 
thereby accounting for the poisoning symptoms of vomiting, abdominal cramps, 
nausea, salivation, and sweating. Acetylcholine is also a neurotransmitter for the 
somatic motor nervous system, where its accumulation resulted in poisoning symptom 
of involuntary muscle twitching (muscle fasciculation), convulsions, respiratory failure 
and coma. Intoxication of Malathion is treated by the antidote drug Oxime that 
reactivates the acetylcholine esterase and by intravenous injection of the anticholinergic 
(antimuscarinic) drug atropine to antagonize the action of the excessive amounts of 
acetylcholine [El-Metwally et al. 2010]. 
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Fig. 2. Organophosphorus compounds and the suicidal irreversible mechanism-based 
inhibition of the enzyme acetylcholine esterase by diisopropylfluorophosphate. Malathion 
and parathion are organophosphorus insecticides. The nerve gases Tabun and Sarin are 
other organophosphorus compounds.  
Another example of irreversible inhibition is iodoacetate inhibition of the glycolytic 
glyceraldehyde-3-phosphate dehydrogenase (GPD). Iodoacetate is a sulfhydryl compound 
that covalently alkylates and blocks the sulfhydryl group at the active site of the enzyme. 
Iodoacetate also inhibits other enzymes with -SH at the active site (Figure 3).  
 
CH2 COOH
Iodoacetate
GPD Cysteine CH2 SH
IH
I CH2 COOHGPD Cysteine CH2 S
Active glyceraldehyde-3-phosphate
dehydrogenase
Inhibited glyceraldehyde-3-phosphate
dehydrogenase  
 
Fig. 3. The suicidal irreversible mechanism-based inhibition of the enzyme glyceraldehyde-
3-phosphate dehydrogenase by iodoacetate.  
 Allopurinol - the anti-gout drug - is a suicidal irreversible mechanism-based inhibitor of 
the enzyme xanthine oxidase that works as oxidase or dehydrogenase. The enzyme 
commits suicide by initial activating allopurinol into a transition state analog - 
oxypurinol - that bind very tightly to molybdenum-sulfide (Mo-S) complex at the active 
site (Figure 4). This enzyme accounts for the human dietary requirement for the trace 
mineral molybdenum. The molybdenum-sulfide (Mo-S) complex binds the substrates 
and transfers the electrons required for the oxidation reactions.  
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Fig. 4. The suicidal irreversible mechanism-based inhibition of the enzyme xanthine oxidase 
by allopurinol.  
 Guanosine analogue antiviral drug aciclovir - acycloguanosine (2-amino-9-((2-
hydroxyethoxy)methyl)-1H-purin-6(9H)-one), as one of the most commonly-used 
antiviral drugs, it is primarily used for the treatment of herpes simplex and herpes 
zoster (shingles) viral infections. Aciclovir (see Figure 5) started a new era in antiviral 
therapy, as it is extremely selective and low in cytotoxicity. Aciclovir as a prodrug 
differs from previous nucleoside analogues in that it contains only a partial nucleoside 
structure: the sugar ring is replaced by an open-chain structure. It is selectively 
converted into acyclo-guanosine monophosphate (acyclo-GMP) by viral thymidine 
kinase, which is far more effective (3000 times) in phosphorylation than cellular 
thymidine kinase. Subsequently, the monophosphate form is further phosphorylated 
into the active triphosphate form, acyclo-guanosine triphosphate (acyclo-GTP), by 
cellular kinases. Acyclo-GTP is a very potent inhibitor of viral DNA polymerase; it has 
approximately 100 times greater affinity for viral than cellular polymerase. As a 
substrate, acyclo-GTP is incorporated into viral DNA, resulting in chain termination. 
Acyclo-GTP is fairly rapidly metabolized within the cell, possibly by cellular 
phosphatases.  
HN
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Fig. 5. Aciclovir; the prodrug for the suicidal irreversible inhibition of the viral DNA 
polymerase.  
 The antibiotic penicillin is another transition state analog suicidal inhibitor that binds 
irreversibly covalently to serine at the active site of the bacterial enzyme glycopeptide 
transpeptidase. The enzyme is a serine protease required for synthesis of the bacterial 
cell wall and is essential for bacterial growth and survival. It normally cleaves the 
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peptide bond between two D-alanine residues in a polypeptide. Penicillin structure 
contains a strained peptide bond within the β-lactam ring that resembles the transition 
state of the normal cleavage reaction, and thus penicillin binds very readily to the 
enzyme active site. The partial reaction to cleave the imitating penicillin peptide bond 
activates penicillin to bind irreversibly covalently to the active site serine (Figure 6).  
HC
C N
CH
C
H
C
S
Penicillin
HO - Serine-Glycopeptide Transpeptidase;
Free and active
CH3
CH3
COO-
NH
C
R
O
O
HC
C HN
CH
C
H
C
S CH3
CH3
COO-
NH
C
R
O
O
O - Serine-Glycopeptide Transpeptidase;
Covalently bound and inactive
Strained peptide bond
 
Fig. 6. The suicidal irreversible mechanism-based inhibition of the bacterial enzyme 
glycopeptide transpeptidase by the antibiotic penicillin. 
 Aspirin (acetylsalicylic acid) provides an example of a pharmacologic drug that exerts its 
effect through the covalent acetylation of an active site serine in the enzyme 
cyclooxygenase (prostaglandin endoperoxide synthase). Aspirin resembles a portion of 
the prostaglandin precursor that is a physiologic substrate for the enzyme. 
 Heavy metal toxicity is caused by tight binding of a metal such as mercury, lead, 
aluminum, or iron, to a functional group at the active site of an enzyme. At high 
concentration of the toxin, heavy metals are relatively nonspecific for the enzymes they 
inhibit and inhibit a large number of enzymes. For example, it is impossible to specify 
which particular enzyme is implicated in mercury toxicity that binds reactive -SH 
groups at the active sites. Lead developmental and neurologic toxicity is caused by its 
ability to replace the normal functional metal in target enzymes; particularly Ca2+ in 
important enzymes, e.g., Ca2+-calmodulin and protein kinase C. Because of their 
irreversible effect, heavy metals are routinely use as fixatives in histological 
preparations. 
Kinetically, the irreversible inhibitors decrease the concentration of active enzyme and in 
turn decrease the maximum possible concentration of ES complex with ultimate reduction 
in the reaction rate of the inactivated individual enzyme molecules. The remaining 
unmodified enzyme molecules are normally functional considering their turnover number 
and Km. For example: Natural poisons act as Enzyme inhibitors and Inhibitory enzymes 
In nature, animals and plants are rich in poisons as secondary metabolites, peptides and 
proteins that can act as enzyme inhibitors. Natural toxins are small organic molecules and 
act as natural inhibitors for enzymes in metabolic pathways and non-catalytic proteins.  
 Neurotoxins are natural inhibitors, toxic but valuable for therapeutic uses at lower 
doses. For example, glycoalkaloids from Solanaceae family plants (potato, tomato and 
eggplant) act as acetylcholinesterase inhibitors to increase the acetylcholine 
neurotransmitter, muscular paralysis and then death. Many natural toxins are 
secondary metabolites. These neurotoxins also include peptides and proteins. An 
example of a toxic peptide is alpha-amanitin, found in death cap mushroom and acts 
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potent enzyme inhibitor, in this case preventing the RNA polymerase II enzyme from 
transcribing DNA. The algal toxin microcystin is also a peptide and is an inhibitor of 
protein phosphatases. This toxin can contaminate water supplies after algal blooms and 
is a known carcinogen that can also cause acute liver hemorrhage and death at higher 
doses. Proteins can also be natural poisons or antinutrients, such as the trypsin 
inhibitors that are found in some legumes, potato, and tomato. Several invertebrate and 
vertebrate venoms contain protein and peptide enzyme inhibitors for, e.g., plasmin, 
renin and angiotensin converting enzymes. Inhibitory enzymes are enzymes that 
irreversibly inhibit other enzymes by chemically modifying them. In the broad sense, 
they include all proteases and lysosomal enzymes. Some of them are toxic plant 
products, e.g., ricin, a glycosidase that is an extremely potent protein toxin found in 
castor oil beans. It inactivates ribosomes by cleavage the eukaryotic 28S rRNA and 
reduces protein synthesis and a single molecule of ricin is enough to kill a cell.  
4. Reversible inhibition 
Reversible inhibitors may be competitive, noncompetitive, or uncompetitive inhibitors 
relative to a particular substrate. Products of enzymatic reactions are reversible inhibitors of 
the enzymes. A decrease in the rate of an enzyme caused by the accumulation of its own 
product plays an important role in the balance and most economic usage of metabolic 
pathways. It prevents one enzyme in a sequence of reactions from generating a new product 
more than the capacity of the next enzyme in that sequence, e.g., inhibition of hexokinase by 
accumulating glucose 6-phosphate.  
With the reduction in the inhibitor concentration, the enzyme activity is regenerated due to 
the non-covalent association and the reversible equilibrium with the enzyme. The 
equilibrium constant for the dissociation of enzyme inhibitor complexes is known as Ki that 
equals [E][I]/[EI] [Cheng et al. 1973]. The inhibition efffect of Ki on the reaction kinetics is 
reflected on the normal Km and or Vmax observed in Lineweaver-Burk plots; in a pattern 
dependent on the type of the inhibitor [Nelson et al. 2008]. The inhibitor is removable by 
several ways. The three common types of reversible inhibitions are: 
 Competitive reversible inhibition. 
 Uncompetitive reversible inhibition. 
 Mixed reversible inhibition (or non-competitive inhibition). 
4.1 Competitive reversible inhibition  
The competitive inhibitor is structurally related to the substrate and binds reversibly at the 
active site of enzyme and occupies it in a mutually exclusive manner with the substrate. 
Therefore, the competitive inhibitor competes with the substrate for the active site. The 
binding is mutually exclusive because of their free competition. According to the law of 
mass action, relatively higher inhibitor concentration prevents the substrate binding. Since 
the reaction rate is directly proportional to [ES], reduction in ES formation for EI formation 
lowers the rate. Increasing substrate towards a saturating concentration alleviates 
competitive inhibition. In the time enzyme-substrate complex releases the free enzyme and a 
product, the enzyme-inhibitor complex does release neither free enzyme nor a product. 
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Reversible inhibition is of short duration in the biological system because it depends on 
substrate availability and/or rate of the catabolic clearance of the inhibitor (Figure 7). 
Vmax
aKm
1
1
[S]
1
1
Vo
Increases in inhibitor 
concentration
Increases in
E + S            ES             E + P
K1 K2
K-1
Ki
E + I EI + S No product
 
Fig. 7. The equation and the effect of the competitive inhibitor on the double reciprocal plot 
of the substrate-reaction rate relationship.  
Kinetically, the inhibitor (I) binds the free enzyme reversibly to form enzyme inhibitor 
complex (EI) that is catalytically inactive and cannot bind the substrate. The competitive 
inhibitor reduces the availability of free enzyme for the substrate binding. Thus, the Km of 
the normal reaction is increased to a new Km (aKm) as a function of the inhibitor 
concentration (expressed in the "a" factor - apparent Km in presence of the inhibitors), where 
the substrate concentration at Vo = ½ Vmax is equal to aKm. The "a" can be calculated from the 
change in the slope of the line at a given inhibitor concentration; 
 
I
I
[I] [E][I]
a = 1 + , where, K =
K [EI]
 (1) 
Therefore, competitive inhibitors do not affect the turnover number (active site catalysis per 
unit time) or the efficiency of the enzyme because once enzyme is free, enzyme behaves 
normally. The Michaelis-Menten equation for competitive inhibitors becomes 
 max
o
m
V [S]
V =
aK + [S]
 (2) 
 Consequently, the double reciprocal form of the equation is also modified so as the line 
slope becomes  m
max
aK
V
 and the intercept with y-Axis stays at 1
Vmax
  but the intercept with 
the x-axis at 
m
1
-
aK
 will differ according to the concentration of the competitive inhibitor. 
The later property is characteristic for competitive inhibitors. 
Examples include the classical competitive inhibitory effect of malonic acid on succinate 
dehydrogenase (SD) of the Krebs' cycle that reversibly dehydrogenates succinate into 
fumarate. Other less potent competitive inhibitors of succinate dehydrogenase include; 
oxalate, glutamate and oxaloacetate. The common molecular geometric feature of these 
compounds is the presence of two negatively charged -COOH groups suggesting that the 
active site of the flavoprotein SD has specifically positioned two positively charged binding 
groups (Figure 8). 
www.intechopen.com
 
Enzyme Inhibition: Mechanisms and Scope 13 
Succinate
CH2
COO
-
COO
-
COO
-
COO
-
COO
-
CH2
COO
-
C O
COO
-
CH2
CH2
CH
COO
-
H2N
Malonate
Oxalate
SD-FAD SD-FADH2
CH
COO
-
CH
COO
-
Fumarate
Oxaloacetate
Succinate 
dehydrogenase
Glutamate
CH2
COO
-
CH2
COO
- +
+
SD
 
Fig. 8. The substrate and different competitive inhibitors of succinate dehydrogenase (SD). 
Methotrexate - competitive inhibitor of dihydrofolate reductase (DHFR) is another example. 
The drug is used as anticancer antimetabolite chemotherapy particularly for pediatric 
leukemia. It hinders the availability of tetrahydrofolate as a carrier for one-carbon moieties 
important for anabolic pathways -particularly synthesis of purine nucleotides for DNA 
replication (Figure 9).  
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Fig. 9. The substrate and methotrexate as a competitive inhibitor for dihydrofolate 
reductase.  
Sulfanilamides - the simplest form of Sulfa drugs - were among earliest antibacterial 
chemotherapeutic drugs classified as enzyme inhibitors. They are competitive inhibitors of 
the bacterial folic acid synthesizing enzyme system from p-aminobenzoic acid. Bacterial 
cannot absorb pre-made folate that is necessary to be synthesized de novo. Structural 
similarity of sulfanilamide (and other sulfas derived from it) to p-aminobenzoic acid made 
them competitive inhibitors to the enzyme (Figure 10).  
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H2N COOH
H2N SO2
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Fig. 10. The p-aminobenzoic acid substrate and sulfanilamide as a competitive inhibitor 
during the bacterial folate synthesis. 
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Male erectile impotence was a major medical problem. Now a group of chemicals with 
molecular structural similarity to cGMP is promising that competitively inhibit the cGMP-
phosphodiesterase-5. They include sildenafil citrate (Viagra; Figure 11), vardenafil (Levitra) 
and tadalafil (Cialis). The inhibition of this enzyme that has a limited tissue distribution 
including the penile cavernous tissue spares cGMP. Accumulation of cGMP leads to smooth 
muscle relaxation (vasodilation) of the intimal cushions of the helicine arteries, resulting in 
increased inflow of blood and an erection.  
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Fig. 11. The cGMP substrate and sildenafil a competitive inhibitor of the cGMP-
phosphodiesterase-5. 
Another example of these substrate mimics competitive inhibitors are the peptide-based 
protease inhibitors, a very successful class of antiretroviral drugs used to treat HIV, e.g., 
ritonavir that contains three peptide bonds (see Figure 12).  
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Fig. 12. The peptide-based competitive protease inhibitor ritonavir. 
Reversible competitive inhibitors of acetylcholinesterase, such as edrophonium, physostigmine, 
and neostigmine, are used in the treatment of myasthenia gravis and in anesthesia. The 
carbamate pesticides are also examples of reversible acetylcholinesterase inhibitors.  
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4.2 Uncompetitive reversible inhibition  
Uncompetitive inhibitor has no structural similarity to the substrate. It may bind the free 
enzyme or enzyme substrate complex that exposes the inhibitor binding site (ESI). Its binding, 
although away from the active site, causes structural distortion of the active and allosteric sites 
of the complexed enzyme that inactivates the catalysis. This leads to a decrease in both Km and 
Vmax. Increasing substrate towards a saturating concentration does not reverse this type of 
inhibition and reversal requires special treatment, e.g., dialysis. This type of inhibition is also 
encountered in multi-substrate enzymes, where the inhibitor competes with one substrate (S2) 
to which it has some structural similarity and is uncompetitive for the other (S1). The reaction 
without the inhibitor would be; E + S1  ES1 + S2  ES1S2  E + Ps and with uncompetitive 
inhibitor becomes; E + S1  ES1 + I  ES1I (prevents S2 binding)  no product. It is a rare 
type and the inhibitor may be the reaction product or a product analog.  
Kinetically, uncompetitive inhibition modifies the Michaelis-Menten equation by (a') factor 
that proportionates with the inhibitor concentration to be: 
 m ax
o
m
V [S]
V =
K + a'[S]
 (3) 
and in the double-reciprocal equation to be: 
 m
o max max
K1 a' 1
= + X
V V V [S]
 (4) 
while y-intercept is at 
max
a'
V
and x-intercept is at '
m
a
K
 , whereas, the line slope stays m
max
K
V
. 
This gives a number of lines in the Lineweaver-Burk plot that are parallel to the normal line 
with decreased 1/Vmax and –a'/Km proportional to concentrations of the uncompetitive 
inhibitor. The later is characteristic to uncompetitive inhibition (Figure 13).  
Vmax
Km
a' [S]
1
1
Vo
Increases in inhibitor 
concentration and 
Decreases in a'/Vmax
Decreases in
a'
K2E + S             ES            E + P
K1
K-1 Ki
No product
I
ESI
 
Fig. 13. The equation and the effect of the uncompetitive inhibitor on the double reciprocal 
plot of the substrate-reaction rate relationship. 
Uncompetitive reversible inhibition is rare, but may occur in multimeric enzymes. Examples 
of uncompetitive reversible inhibitors include; inhibition of lactate dehydrogenase by 
oxalate; inhibition of alkaline phosphatase (EC 3.1.3.1) by L-phenylalanine, and, inhibition of 
the key regulatory heme synthetic enzyme; δ-aminolevulinate synthase and dehydratase 
and heme synthetase by heavy metal ion, e.g., lead. Heavy metals, e.g., lead, form 
mercaptides with -SH at the active site of the enzyme (2 R-SH + Pb  R-S-Pb-S-R + 2H). 
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Oxidizing agents, e.g., ferricyanide also oxidizes -SH into a disulfide linkage (2 R-SH  R-S-
S-R). Reversion here requires treatment with reducing agents and/or dialysis. 
4.3 Mixed (noncompetitive) inhibition 
The mixed type inhibitor does not have structural similarity to the substrate but it binds 
both of the free enzyme and the enzyme-substrate complex. Thus, its binding manner is not 
mutually exclusive with the substrate and the presence of a substrate has no influence on 
the ability of a non-competitive inhibitor to bind an enzyme and vice versa. However, its 
binding - although away from the active site - alters the conformation of the enzyme and 
reduces its catalytic activity due to changes in the nature of the catalytic groups at the active 
site. EI and ESI complexes are nonproductive and increasing substrate to a saturating 
concentration does not reverse the inhibition leading to unaltered Km but reduced Vmax. 
Reversal of the inhibition requires a special treatment, e.g., dialysis or pH adjustment. Some 
classifications differentiate between non-competitive inhibition as defined above and mixed 
inhibition in that the EIS-complex has residual enzymatic activity in the mixed inhibition. 
Kinetically, mixed type inhibition causes changes in the Michaelis-Menten equation so as  
 max
o
m
V [S]
V =
aK + a'[S]
 (5) 
Mixed type inhibition - as the name imply - has a change in the denominator with Km 
modified by factor (a) as in competitive inhibition, and [S] modified by factor (a') as in 
uncompetitive inhibition. In the double reciprocal equation 6, 
 m
o max max
aK1 a' 1
= + X
V V V [S]
 (6) 
A line slope is m
max
aK
V
, and the intercept with y-axis is at
max
a'
V
and with x-axis is at 
m
a'
aK
. This 
results in progressive decreases in Vmax and progressive increases in Km proportional to the 
increase in the mixed inhibitor concentration. The double reciprocal plot shows a number of 
lines reflecting decreases in Vmax/increases in Km but their intercept is to the left of the y-
axis. Mixed type inhibitor would be called non-competitive only if [a = a'], where, it will 
only lower Vmax without affecting the Km (Figure 14). 
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Fig. 14. The equation and the effect of the mixed type (noncompetitive) inhibitor on the 
double reciprocal plot of substrate-reaction rate relationship. 
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Examples of noncompetitive inhibitors are mostly poisons because of the crucial role of the 
targeted enzymes. Cyanide and azide inhibits enzymes with iron or copper as a 
component of the active site or the prosthetic group, e.g., cytochrome c oxidase (EC 
1.9.3.1). They include the inhibition of an enzyme by hydrogen ion at the acidic side and 
by the hydroxyl ion at the alkaline side of its optimum pH. They also include inhibition 
of; carbonic anhydrase by acetazolamide; cyclooxygenase by aspirin; and, fructose-1,6-
diphosphatase by AMP. Cyanide binds to the Fe3+ in the heme of the cytochrome aa3 
component of cytochrome c oxidase and prevents electron transport to O2. Mitochondrial 
respiration and energy production cease, and cell death rapidly occurs. The central 
nervous system is the primary target for cyanide toxicity. Acute inhalation of high 
concentrations of cyanide (e.g., smoke inhalation during a fire and automobile exhaust) 
provokes a brief central nervous system stimulation rapidly followed by convulsion, 
coma, and death. Acute exposure to lower amounts can cause lightheadedness, 
breathlessness, dizziness, numbness, and headaches. Cyanide is present in the air as 
hydrogen cyanide (HCN), in soil and water as cyanide salts (e.g., NaCN), and in foods as 
cyanoglycosides. Comparison of the three types of the reversible enzyme inhibitors is 
presented in Table 1. 
In a special case, the mechanism of partially competitive inhibition is similar to that of non-
competitive, except that the EIS complex has catalytic activity, which may be lower or 
even higher (partially competitive activation) than that of the enzyme-substrate (ES) 
complex. This inhibition typically displays a lower Vmax, but an unaffected Km value. We 
compare three main types of inhibitors in terms of reaction properties as shown in Table 1 
and Figure 15. 
 
Competitive inhibitor Uncompetitive inhibitor Mixed  
(noncompetitive inhibitor) 
 The inhibitor binds the 
catalytic/substrate 
binding site.  
 It competes with 
substrate for binding.  
 Inhibition is reversible 
by increasing substrate 
concentration. 
 Vmax  constant, the 
substrate concentration 
has to be increased as 
reflected on increased 
Km. 
 Substrate binding 
exposes the inhibitor 
binding site away from 
the catalytic/substrate 
binding site.  
 Increasing substrate 
concentration does not 
reverse the inhibition. 
 The inhibited reaction 
rate parallel the normal 
one as reflected on 
decreased both Vmax and 
Km. 
 The inhibitor binds each 
of the free enzyme and 
the substrate-enzyme 
complex away from the 
catalytic/substrate 
binding site.  
 Increasing substrate 
concentration does not 
reverse the inhibition. 
 Only Vmax is decreased 
proportionately to 
inhibitor concentration,  
 Km is unchanged since 
increasing substrate 
concentration is 
ineffective. 
Table 1. Comparison of the different types of reversible inhibition is shown in Table with a 
quick view of mechanism in sketches as below. 
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Fig. 15. Sketch of three different enzyme inhibition by competitive, uncompetitive and 
noncompetitive types are shown with illustration of enzyme-substrate or inhibitor binding, 
kinetics and graphs.  
In last decade, role of membrane receptors was explored in relation with enzyme inhibition. 
Membrane receptors or transmembrane proteins bind with natural ligands such as 
hormones, neurotransmitters in tissue membranes. Receptor-ligand binding modulates the 
binding of drugs with enzyme. Such ligand binding behavior also influences the analysis of 
competitive, uncompetitive and noncompetitive inhibition by biological effect of prodrugs 
on enzymes. It usually involves a shape change in the receptor, a transmembrane protein, 
which activates intracellular activities. The bound receptor usually does not directly express 
biological activity, but initiates a cascade of events which leads to expression of intracellular 
activity. However, occupied receptor actually expresses biological activity itself. For 
example, the bound receptor can acquire enzymatic activity, or become an active ion 
channel with similar competitive, noncompetitive behavior. Drugs targeted to membrane 
receptors can have biological effects similar to the natural ligands, they are called agonists, 
or conversely they may inhibit the biological activity of the receptor, they are called 
antagonists [Jakobowski 2010a]. 
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4.4 Agonist 
An agonist or test drug or substrate is similar to natural ligand and binds with receptor to 
produce a similar biological effect as the natural ligand. Agonist binds at the same binding 
site in competition with natural ligand to show full or partial response. So, it is called partial 
agonist. If receptor has a basal (or constitutive) activity in the absence of a bound ligand, it 
is called inverse agonist. If either the natural ligand or an agonist binds to the receptor site, 
the basal activity is increased. If an inverse agonist binds, the activity is decreased. Ro15-
4513 and benzodiazepines (Valium) bind with the GABA receptor. As a result, GABA 
receptor is "activated" to become a ion channel allowing the inward flow of Cl- into a neural 
cell, inhibiting neuron activation. Ro15-4513 binds to the benzodiazepine site, which leads to 
the opposite effect of valium, the inhibition of the receptor bound activity - a chloride 
channel as shown in Figure 16.  
 
Fig. 16. A sketch is shown for membrane receptor binding with ligand (agonist) acting like 
as enzyme. Reproduced with permission [Jakobowski 2010a]. 
4.5 Antagonist 
Antagonist or test inhibitor can inhibit the effects of the natural ligand (hormone, 
neurotransmitter), agonist, partial agonist, and inverse agonists. We can think of them as 
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inhibitors of receptor activity behaving as competitive, noncompetitive and irreversible 
antagonists as shown in Figure 17. For further details, readers are requested to read 
advanced text book [Nelson et al. 2008, Dixon and Webb 1979]  
 
 
 
Fig. 17. Sketch is shown for membrane receptor binding with ligand (acting as agonist) and 
antagonist (acting as inhibitor) in competition with agonist to bind with enzyme. 
Reproduced with permission [Jakobowski 2010a] 
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5. Inhibition by physiological modulators 
5.1 Temperature of reaction 
Some endothermic or exothermic chemical compounds change the temperature of reaction. 
Enzyme reaction experiences inhibition at higher or lower than optimal physiological 
temperature. For example, human body optimal temperature of human body is 37 oC. For 
most of the enzyme reactions, enzyme activity usually increases at 0 to about 40-50 oC in the 
absence of catalysts. As a general rule of thumb, reaction velocities double for each 
increment of 10oC rise. At higher temperatures, the activity decreases dramatically as the 
enzyme denatures as shown in Figure 18. 
 
Fig. 18. Figure shows the effect of temperature change on the rate of enzyme reaction. Notice 
the initial rise of rate of reaction and sudden fall near to optimal temperature 37-42 °C.  
5.2 Hydrogen ion concentration or pH of reaction 
Think of all the things that pH changes might affect. Many chemicals such as acids or 
alkaline chemical compounds if mixed in enzyme reaction medium can change the pH. As a 
result, reaction rate changes. It might  
 affect E in ways to alter the binding of S to E, which would affect Km  
 affect E in ways to alter the actual catalysis of bound S, which would affect kcat  
 affect E by globally changing the conformation of the protein  
 affect S by altering the protonation state of the substrate  
The easiest assumption is that certain side chains necessary for catalysis must be in the correct 
protonation state. Thus, some side chain, with an apparent pKa of around 6, must be 
deprotonated for optimal activity of trypsin which shows an increase in enzyme activity with 
the increase in range centered at pH 6. Which amino acid side chain would be a likely 
candidate to participate in enzyme inhibition? It all depends on net charge on active group of 
each amino acid in the active site chain. The pH of reaction thus depends on net pKa value of 
amino acids and presence of acid or alkaline nature of substrate effects on enzyme kinetics by 
formation of EH, ESH as shown in Figure 19. It can be modeled at the chemical and 
mathematical level to calculate velocity(v), Vm(apparent) and Km(apparent) as shown in 
Equations 7-9. Different enzymes show different behavior of enzyme catalyzed reactions such 
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as chymotrypsin, cholinesterase, papain, and papsin show distinct graphs (see Figure 20). For 
further details, readers are requested to read text books [Nelson et al. 2008, Berg et al. 2011] 
 
  
Vm app S
V =
Km app +S
 (7) 
 
Vm
Vm app =
1+H+/Kes1+Kes2 /H+  (8) 
 
Km(1+H+/Ke1+Ke2/H+)
Km app=
1+H+/Kes1+Kes2 /H+  (9) 
Fig. 19. Chemical equations showing the mechanism of pH effects on enzyme catalyzed 
reactions. Different mathematical equations 7-9 illustrate the modeling pH effects on 
enzyme catalyzed reactions. 
5.2.1 Three dimensional nature of enzyme-inhibitor complex at enzyme active site 
The role of non-covalent interactions such as hydrogen bonding, hydrophobic interaction 
and orientation of inhibitor and enzyme in an organized fashion was well described in 
classic paper [Amtul et al., 2002]. 3D nature of enzyme reaction can be understood as 
following. There are two sites on enzyme molecule: 1. at allosteric site, inhibitor binds with 
enzyme, and 2. at active site, substrate binds with enzyme. However, substrate and inhibitor 
interact with each other by non-covalent interactions of their chemical groups. Inhibitors 
interact at allosteric site and known as ‘pharmacohores’. Presently, structure-based design 
and testing, mechanistic biological approach is a state-of-art to develop new pharmacohores. 
The non-covalent interactions determine the chemoselectivity of the substrate and enzymes 
during formation of the ESI complex. In other words, ESI complex provides enzyme as a 
platform to perform catalysis. 3D geometrical shape and topology of active site match with 
orientation of chemical groups in substrate molecule that fit together in a ‘lock and key’ 
arrangement. Several possibilities happen to make enzyme-inhibitor complexes such as 
bidentate, tri-, tetra- and polydentate, trigonal, pyramidal, tetrahedral, polyhedral charge 
transfer complexes due to co-ordinate interactions between metallic co-factor with 
hydrophilic groups on inhibitor(s). In this process, geometry of amino acid side chains at 
allosteric site changes due to hydrogen bonding between amino acid residues. Suboptimal 
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Fig. 20. Graphs of different pH effects on enzyme catalyzed reactions as log Vm(app) and 
Vm/Km(app) are shown on left. Different enzymes such as chymotrypsin, cholinesterase, 
pepsin and papain are illustrated with different rates of enzyme reaction. Reproduced with 
permission [Jakobowski 2010a] 
interactions of metal-solvent, oxygen-water molecular bridge, free energy content loss, 
subunit-subunit biophysical interactions as a result play a significant role in inhibitor-
enzyme complex formation and completion of enzyme catalysis. 
For more details, readers are requested to read recent reference papers on 3D mechanistic 
studies on enzymes. Specific example on urease is cited in chapter 11 in this book. Now 
science is shifting to develop crystallized enzyme molecules, better structural-functional 
relationship in enzyme catalysis and immobilized enzyme chips. 
In following description, factors are discussed on different practical considerations that 
influence the enzyme reaction rates, enzyme inhibition kinetics, % binding efficiency on 
enzyme solid support with a glimpse of known theories and concepts on real-time, cheaper, 
economic, user-friendly immobilized enzyme technology.  
When actual and practical considerations are analyzed to work in enzyme reactor, the 
scenario becomes complicated. Several factors such as inhibitor chemical state, substrate 
structure, enzyme 3D conformation or peptide subunit interactions, physiological reaction 
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conditions in reactor and enzyme carrier supports also contribute in inhibition kinetics and 
rates of reaction to form ES,ESI and P. Every year list of new factors grows in new enzyme 
systems. 
Author believes that more and more contributory factors introduced, will influence enzyme 
reaction rate kinetics and more and more additive kinetic constants are introduced with new 
variants to define the action of inhibitors on enzyme catalysis.  
Other factors to keep in mind for new possibilities are: 
1. enzyme autoinhibition and enzyme molecular structural-functional factors affecting 3D 
conformation of active site compatible with active groups of substrate or inhibitor 
2. porosity and diffusion across the enzyme support material and availability of exposed 
active sites to react 
3. real-time recording the instant formation of ESI or ES or EP or EI on solid phase enzyme 
support organic chip 
4. sustrate-inhibitor interactions, % binding of active site with each additive 
5. computer based semi-corrected or averaged calculations of kinetic constants of 
inhibition kinetics 
6. thermodynamic states of the enzyme reaction in reactor and fluctuating physiological 
and physical states of substrate, inhibitor, enzyme complexes in reactor. 
7. synergy of inhibitors, substrate, subunits in enzyme on active site 
For all these factors and details, readers are expected to read advanced text books on 
enzyme inhibition and enzyme engineering. Readers will experience a wide variation in the 
scientific analysis of enzyme inhibition data in different enzyme reactors used in different 
studies. High efficiency with desired results of enzyme inhibitors is the new challenges to 
optimize reaction, scale-up, and phase out unwanted physiological factors from reaction. In 
following section, these issues are addressed. Author believes that above mentioned 
description is just iceberg from a large hidden treasure or unknown factors contributing 
enzyme inhibition to give desired outcome.  
6. Immobilized enzyme systems 
In search of economic, efficient and practical enzyme platforms to test enzyme inhibitors, 
new user-friendly immobilized enzyme technology is available now. It is based on principle 
that an enzyme molecule is contained within confined space for the purpose of retaining 
and re-using enzyme on solid medium in processing system or equipment. There are many 
advantages of immobilized enzymes and methods of immobilization such as low cost, 
suitability of reusable model system in membrane-bound enzymes in cell. However, some 
disadvantages are expansive methods of adsorption or covalent bound or matrix trapping or 
membrane trapping immobilization methods, low measurement of enzyme activity with 
mass transfer limitations. For knowledge sake, the entrapment of enzyme molecules on 
matrix, diffusion phenomenon and kinetics are important to understand. A brief description 
is given for interested readers on classic concepts and scientific basis of porous or non-
porous enzyme supports, theory of enzyme immobilization and efficiency of reaction 
outcome. For more details of each aspect, readers are requested to read individual research 
papers.  
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Matrix entrapment is done by mixing enzyme solution with polymer fluid in matrices such 
as Ca-alginate, agar, polyacrylamide, collagen. Membrane entrapment is done by confining 
enzyme solutions between semi-permeable membrane hollow fibers made of nylon, 
cellulose, polysulfone, polyacrylate etc. Surface immobilization by adsorption is done by 
attaching enzymes on stationary solids such as alumina, porous glass, cellulose, ion-
exchange resin, silica, ceramic, clay, starch etc. by physical forces keeping active sites intact. 
Covalent bonding is done by enzyme retention on support surfaces by covalent binding 
between functional groups such as amino, carboxylic, sulfhydryl, hydroxyl groups on the 
enzyme and those on the support surface keeping enzyme active site(s) free (see Figure 21) 
[Laider et al. 1980]. 
 
Fig. 21. Scheme of immobilization of enzyme is shown with chemical groups involved in 
binding of enzyme on solid surface. Reproduced with permission from reference Lieder et 
al.1980. 
Diffusional limitations are observed to various degrees in all immobilized enzyme systems. 
This occurs because substrate must diffuse from the bulk solution up to the surface of the 
immobilized enzyme prior to reaction. The rate of diffusion relative to enzyme reaction rate 
determines whether limitations on intrinsic enzyme kinetics is observed or not as shown in 
Figures 22 [Laider et al.1980]. However, rate of diffusion across and within matrix is 
determinant of immobilized enzyme reaction as shown in Figure 22 and 23.  
In immobilized enzyme reaction, two major effects due to diffusion and product inhibition are 
first observed by Lineweaber-Burk plots in classic study [Rees, 1984]. The diffusional effects 
and product inhibition both influenced the shape of Lineweaver-Burk plot (see Figure 22). In 
case of substrate inhibition effects binding of more than one substrate molecule(s) lead to 
inhibition showing same type of curved Lineweaver-Burk plot as those observed for 
diffusional limitation and product inhibition in immobilized enzymes. Combination of these 
two effects lead to intermediate behavior, such as normal Michaelis-Menten kinetics as shown 
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in Figure 24, 25 by curves [Rees, 1984]. However, immobilized enzyme system also suffers 
from both diffusion and product inhibition effects. As a consequence, it is important to 
consider diffusion effects and product inhibition effects while extracting catalytic parameters 
from kinetic data for immobilized enzyme systems. Use of non-porous support in enzyme 
immobilization minimizes the diffusion effects to some extent.  
   
  pi kkE + S ES EP E + P
   
Fig. 22. A sketch of porous matrix is shown (on left) and a scheme of substrate mass balance 
Equation to calculate rate of immobilized enzyme reaction rs is shown (on right) 
 
Fig. 23. A scheme of substrate mass balance is shown to calculate S with boundary 
conditions. 
Enzyme kinetics predicts the efficiency of reaction. Kinetics of immobilized enzymes 
depends on conformational alterations within the enzyme due to the immobilization 
procedure, or the presence and nature of the immobilization support. Immobilization can 
greatly affect the stability of an enzyme such as any strain into the enzyme will inactivate 
the enzymes under denaturing conditions (e.g. higher temperatures or extremes of pH). An 
example of unstrained multipoint binding between the enzyme and the support to cause 
substantial stabilization is illustrated in Figure 20. From mechanistic standpoint, a lesser 
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conformational change within the protein structure will initiate enzyme inactivation. As a 
result, covalent immobilization processes involve an initial freely-reversible stage. Covalent 
links may form, break and re-form till an unstrained covalently-linked structure is created. 
However, additional stabilization is derived from maximum enzyme-support compatibility, 
least enzyme molecule interactions, least proteolytic and microbiological attacks.  
 
Fig. 24. Effect of one or more inhibitor molecules on enzyme kinetics and their inhibition 
effect dependent on 1/So. Reproduced with permission from Rees et al. 1984. 
 
Fig. 25. A scheme of immobilized enzyme action is shown on non-porous solid support. 
Notice the dependence of Vm on available immobilized enzyme active sites (EL). 
The kinetic constants (e.g. Km, Vmax) of immobilized enzymes may be altered by the process 
of immobilization due to internal structural changes and restricted access to the active site. 
Thus, the intrinsic specificity (k./Km) of such enzymes may well be changed relative to the 
soluble enzyme. An example of trypsin is illustrated in Figure 21, where the freely soluble 
enzyme hydrolyses fifteen peptide bonds in the protein pepsinogen but the immobilized 
enzyme hydrolyses only ten. The apparent value of these kinetic parameters, when 
determined experimentally, may differ from the intrinsic values. This fact may be due to 
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changes in the properties of the solution in the immediate vicinity of the immobilized 
enzyme, or the effects of molecular diffusion within the local environment. The relationship 
between these intrinsic and apparent parameters is shown below in Figure 26. Typically, 
nonporous microenvironment consists of the internal solution plus part of the surrounding 
solution which is influenced by the surface characteristics of the immobilized enzyme. 
Partitioning of substances occurs between these two environments. Substrate molecule (S) 
Intrinsic parameters of the soluble enzyme 
 
Intrinsic parameters of the immobilized enzyme 
 
Apparent parameters due to partition and diffusion 
 
Fig. 26. A schematic cross-section of an immobilized enzyme particle (a) shows the 
macroenvironment and microenvironment. Triangular dots represent the enzyme 
molecules. Courtesy: Pangandai V. Pennirselvam, Ph.D UFRN, Lagoa Nova–Natal/RN 
Campus Universitário. North East, Brazil. 
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diffuses through the surrounding layer (external transport) in order to reach the catalytic 
surface and gets converted to product (P). In order for all immobilized enzyme to be 
utilized, substrate must diffuse within the pores in the surface of the immobilized enzyme 
particle (internal transport) [Pryciak 2008]. The degree of stabilization is determined by 
strength of the gel, and hence the number of non-covalent interactions. As a result, intrinsic 
parameters of enzyme result with specific apparent parameters dependent on partition and 
diffusion as shown in Figure 27. 
 The porosity (e) of the particle can be expressed as ratio of the volume of solution 
contained within the particle to the total volume of the particle. The tortuosity (t) is the 
average ratio of the path length, via the pores, between any points within the particle to 
their absolute distance apart.  
 The tortuosity, which is always greater than or equal to unity, depends on the pore 
geometry. The diagram exaggerates dimensions for the purpose of clarity.  
 The concentration of the substrate at the surface of the particles [Sr] depends on radius 
R or internal concentration [Si] at any smaller radius (r) is the lower value. 
 
Fig. 27. Illustration of the use of multipoint interactions for the stabilization of enzymes. 
(a) -------- activity of free un-derivatized chymotrypsin. (b) ….. activity of chymotrypsin 
derivatized with acryloyl chloride. (c) -- -- -- activity of acryloyl chymotrypsin copolymerized 
within a polymethacrylate gel. Up to 12 residues are covalently bound per enzyme molecule. 
Lower derivatization leads to lower stabilization. (d) ----- activity of chymotrypsin non-
covalently entrapped within a polymethacrylate gel. All reactions were performed at 60°C 
using low molecular weight artificial substrates. The immobilized chymotrypsin preparations 
showed stabilization of up to 100,000 fold, most of which is due to their multipoint nature 
although the consequent prevention of autolytic loss of enzyme activity must be a significant 
contributory factor. Reproduced with permission from Martinek et al, 1977a,b. 
In general, the use of immobilized enzyme can be divided into two major categories of 
applications: in biosensors and bioreactors. However, list is growing in the other fields of 
ecological, environmental, agriculture, health, oceanic, space and earth sciences. 
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7. New developments in art of enzyme inhibition  
Now a day, immobilized enzymes are used in industries and have value as medicinal and 
industrial enzyme products. Good examples of industrial enzymes are amylase, 
glucoamylase, trypsin, pepsin, rennet, glucose isomerase, penicillinase, glucose oxidase, 
lipase, invertase, pectinase, cellulase in medicinal use. With emergence of new inhibitors in 
the quest of drug discovery, several new inhibition mechanisms are expected in case of new 
substrate analogues. New substrate–enzyme active site interactions are envisaged due to 
different binding intricacies. Some examples of emerging concepts are outlined in following 
description and readers are expected to read advanced literature on these applications. 
 Slow-tight inhibition: Slow-tight inhibition occurs when the initial enzyme-inhibitor 
complex EI undergoes isomerizing conformational change to a more tightly binding 
complex. However, the overall inhibition process is reversible. This manifests itself as 
slowly increasing enzyme inhibition. Under these conditions, traditional Michaelis-
Menten kinetics gives a false value of a time-dependent Ki. The true value of Ki can be 
obtained through more complex analysis of the on (kon) and off (koff) rate constants for 
inhibitor association.  
 Substrate and product inhibition: Substrate and product inhibition is where either the 
substrate or product of an enzyme reaction inhibits the enzyme's activity. This 
inhibition may follow the competitive, uncompetitive or mixed patterns. In substrate 
inhibition there is a progressive decrease in activity at high substrate concentrations. 
This may indicate the existence of two substrate-binding sites in the enzyme. At low 
substrate, the high-affinity site is occupied and normal kinetics is followed. However, at 
higher concentrations, the second inhibitory site becomes occupied, inhibiting the 
enzyme. Product inhibition is often a regulatory feature in metabolism and can also be a 
form of negative feedback; see allosteric regulation [Pryciak 2008, Bashor 2008]. 
 Antimetabolites: They are chemicals that interfere with the normal metabolism of 
normal biochemical metabolite(s). This in most of case is due to their structural 
similarity to such physiological substrates and therefore works as competitive enzyme 
inhibitors. They include antifolates such as methotrexate, hydroxyurea and purine and 
pyrimidine analogues. They are mainly used as cytotoxic anticancer drugs through 
inhibiting DNA and RNA synthesis and cell division. An example of nitroimidazole is 
described in detail on its metabolic effects at cellular level in this book [Sharma 2012a].  
 Antienzyme: Intestinal parasites, e.g., Ascaris, protect themselves from digestion by 
expressing on their surface substances that are protein in nature which inhibit the action 
of digestive enzymes, e.g., pepsin and trypsin. The blood plasma and extracellular 
fluids are containing several types of protease inhibitors particularly important in 
controlling the blood clot formation and dissolution and matrix and cytokine 
homeostasis. Most of these inhibitors are peptides and several of them are also isolated 
from raw egg white, potatoes, tomatoes and Soya bean and other plant sources. Most of 
the natural peptide protease inhibitors are similar in structure to the amino acid 
sequence of the peptide substrates of the enzyme. Designed peptide protease inhibitors 
are important drugs, e.g., captopril that is a metalloprotease angiotensin-converting 
enzyme peptide inhibitor. Inhibiting this enzyme prevent activation of angiotensin and 
therefore prevent vasoconstriction to lower blood pressure. Crixivan is an anti-
retroviral aspartyl protease peptide inhibitor used in the treatment of Human 
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Immunodeficiency Virus (HIV)-induce acquired immunodeficiency syndrome (AIDS). 
It inhibits the HIV protease that cleaves the large multidomain viral protein into active 
enzyme subunits. Because these peptide inhibitors may not be specific, they have 
several side-effects as drugs.  
 Antibodies against several nonfunctional plasma enzymes have clinical diagnostic 
importance since they are longer living than the enzyme itself and hence reflect the 
disease history better. In this respect, autoimmune antibodies are clinically important in 
diagnosis of autoimmune diseases, e.g., anti-glutamic acid decarboxylase antibodies in 
type 1 diabetes mellitus. 
 Biosensors: Light inhibits most enzyme activity although some enzymes, e.g., amylase 
are activated by red or green light and also specific DNA repairing enzymes (e.g., UV-
specific endonuclease) are activated by the blue and UV light. Ultraviolet rays and 
ionizing radiations cause denaturation of most enzymes. Most enzymes contain 
sulfhydryl (-SH) groups at their active sites which upon oxidation by oxidants and free 
radicals by oxidants and free radicals inactivate the enzyme. Examples: Effect of 
radiations, light and oxidants on the rate of the enzyme catalyzed reaction. 
 Other application of membrane bound redox enzymes constitutes them as a scaffolding 
enzyme arrangement into systems for multi-step catalytic processes. The reconstruction 
of portions of this redox catalytic machinery, interfaced to an electrical circuit leads to 
novel biosensing devices or biosensors. An example of nitric oxide synthase enzyme is 
cited in this book [Sharma, 2012b].  
 In EzNET® water purifying system, nitrate pollution is eliminated. Enzyme is 
immobilized on “beads” with an electron-carrying dye as shown in Figure 28. 
Reduction of nitrate to environmentally safe nitrogen gas is driven by a low voltage 
direct current. 
 
 
 
Fig. 28. EzNET® system shows immobilized enzyme on “beads” with an electron-carrying 
dye. In this system, reduction of nitrate generates environmentally safe nitrogen gas driven 
by a low voltage direct current. Source: The Nitrate Elimination Co., Inc. 2000. 
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 In biolumescence detection for toxicity of HPV chemicals or drug development, 62 kDa 
MW oxygenase (yellow green light emitted at 560 nm) enzyme gives 88 photon/cycle 
light output proportional to [ATP] according to:  
Luciferin + luciferase + ATP  luciferyl adenylate-luciferase + pyrophosphate 
Luciferyl adenylate-luciferase + O2  Oxyluciferin + luciferase + AMP + light 
Strong inhibition of luciferase by chloroform or HPV chemicals indicates the efficiency of 
immobilized recombinant luciferase enzyme system as shown in Figure 20. Inhibition by 
chloroform is much reduced in the mutant Luciferase compared to the wild type Luciferase 
as shown in Figures 29, 30. 
 
Source: Kim et al. AIChEngg Annual Meeting 2003, San Francisco, CA. 
Fig. 29. A sketch of recombinant luciferase is shown illustrating the gene clone. 
 In the search for new therapeutics, the high throughput screening (HTS) of ligands for key 
target proteins, enzymes represent the principal hit identification tool for early drug 
discovery [Bartolini et al. 2009]. However, output depends on cost-based or amount-based 
limitation of target availability, need of speed, automation and easy coupling of the 
enzyme assay with separation systems (affinity chromatography of immobilized proteins) 
and appropriate detectors. Good example is targeting in drug discovery represented by 
enzyme inhibition mechanism in monolithic immobilized enzyme reactors (IMERs) to 
represent different phases of the drug discovery pathway-starting with active compounds 
(hit) identification, through drug development and lead optimization, early ADMET 
(absorption, distribution, metabolism, excretion, toxicity) studies and quality control of 
protein drugs. Some details are described in chapters in this book [Bartolini et al. 2005, 
2007]. Interested readers are requested to read advanced text books on these 
aspects. Different IMER have own requirements for optimal performances to show an 
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increased data output, reliability and stability to translate into cost reduction for potential 
applications in pharmacy industry [Bartolini et al. 2005, 2007]. 
 
 
  
 
Source: Kim et al. AIChEngg Annual Meeting 2003, San Francisco, CA. 
Fig. 30. Inhibition of luciferase activity by increasing the concentration of chloroform. 
8. Softwares and computerization in enzyme inhibition kinetics 
Recently softwares have popped up to visualize custom visual interface to see curve fits in 
real-time, graph transforms, equations using kinetic data entry in terms of substrate, inhibitor, 
activator, velocity, and standard deviation of the velocity. Data tables are directly generated 
linked to the Fitting Panel of software. The data and results analysis is transferred in user-
friendly lay-out, ANOVA window, % inhibition using Monte-Carlos fits, and receptor or 
ligand binding calculator. For interested readers, VISUALENZYMICS 2010® is available for 
statistical analysis for enzyme kinetics.[ http://www.softzymics.com/visualenzymics.htm].  
9. Limitations and challenges 
Above mentioned description on mechanism and applications shows a clear issue on need 
of careful analysis for enzyme inhibition factors, presumptions of enzyme reaction, use of 
new immobilized enzyme support and enzyme recording/monitoring methods. Challenge 
is that most of times, basic presumptions do not hold true in enzyme reactors and addition 
of new factors further complicate the calculation of reactor outcome. Most of the times, 
computer based kinetic calculations average out outcome as less realistic with more chances 
of variants. Other major challenge is that each time enzyme reactor outcome depends on 
individual inhibitor and individual enzyme reactor at different times. It is less reproducible 
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and unpredictable because of synergy, interplay of known and unknown physical, 
physiological, biological, molecular factors affecting reaction kinetics.  
10. Impact of enzyme inhibition science in business 
The major current and emerging therapeutic markets for enzyme inhibitors used in human 
therapeutics are very high. New information is available on biochemistry for enzyme 
inhibitors and classes of enzyme inhibiting products with broad current or potential 
therapeutic applications in large markets. However, more than 100 enzyme inhibitors are 
currently marketed and double than those are under development. A better understanding 
of the emerging enzyme inhibitors on enzyme mechanism is main key. These include 
selected indications for asthma and chronic obstructive pulmonary disease (COPD), 
cardiovascular diseases, erectile dysfunction, gastrointestinal disorders, hepatitis B virus 
infection, hepatitis C virus infection, herpesvirus infections, human immunodeficiency virus 
(HIV)/acquired immune deficiency syndrome (AIDS) and rheumatoid arthritis and related 
inflammatory diseases. Key information from the business literature and thorough enzyme 
inhibition research is the basis of expert opinion on commercial potential and market sizes 
from enzyme industry professionals. Since initial reports on chemical immobilization of 
proteins and enzymes first appeared ∼30 years ago, immobilized proteins are now widely 
used for the processing of products in industries from food business to environmental 
control. In recent years, use of chemical immobilization was extended to immobilized 
antibodies or antigens in bioaffinity chromatography. In coming years, it is speculated that 
immobilization techniques of proteins and enzymes will have greater impact on point-of-
care medical and health business.  
11. Conclusion 
Enzyme inhibition is significant biological process to characterize the enzyme reaction, 
extraction of catalysis parameters in bio-industry and bioengineering. Conceptual models of 
inhibition define the interactions of substrate-enzyme or inhibitor-enzyme or both substrate-
enzyme-inhibitor in the moiety of active site. In recent years, application of enzymes and 
enzyme inhibition science have gone in healthcare, pharmaceutical, bio-industries, 
environment, and biochemical enzyme chip industries with great impact on healthcare and 
medical business. Last decade has shown the measurement and accuracy of enzyme 
detection up to the scale of picometer and enzyme industry is entering in the area of 
picotechnology. Immobilized enzyme technology has given a new way of economic tools in 
drug discovery and biosensor industry. Every year new enzyme inhibitors are discovered 
useful as drugs but success still needs to minimize challenges. 
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